By Ben Hansel, Senior Financial Editor 247MarketNews
DENVER, Colo. (247MarketNews) — Lexeo Therapeutics (NASDAQ:LXEO) delivered its most encouraging clinical update yet for LX2020, an experimental gene therapy targeting PKP2-associated arrhythmogenic cardiomyopathy (PKP2-ACM). As a result, the FDA is open to considering non-sustained ventricular tachycardia (NSVT) as a primary surrogate endpoint in a pivotal trial supporting potential accelerated approval.
The interim data revealed that seven participants receiving the higher dose of LX2020 showed an average 80% reduction in NSVT burden and a 44% reduction in premature ventricular contractions (PVCs) at their latest assessments compared with baseline. Six of seven improved on NSVT, while five of seven improved on PVCs. Five also reported symptom improvement.
10 people received treatment, including seven in the high-dose groups. Nine participants had at least 12 months of follow-up as of the October 15 data cutoff. HEROIC-PKP2 is an open-label, single-arm study, meaning there is no untreated control group against which to measure the results. The reported percentages are averages, not evidence that every patient experienced an 80% improvement.
There is, however, a meaningful progression from Lexeo’s January 2026 update. At that point, the company reported a 22% mean improvement in NSVT among five high-dose participants with more than six months of follow-up. The latest 80% figure, based on seven participants and longer observation, suggests the response may deepen over time, an encouraging signal.
NSVT is an abnormal heart rhythm associated with the disease’s risk of more serious arrhythmias. If regulators ultimately accept it as a surrogate endpoint, Lexeo may be able to pursue accelerated approval without first demonstrating a reduction in sudden cardiac death or other hard clinical outcomes in a lengthy pivotal trial.
Lexeo expects to finalize the pivotal study design, statistical analysis plan and confirmatory evidence strategy in the first half of 2027, with trial initiation targeted for later in 2027.
Lexeo reports no clinically significant complement activation and no trial discontinuations among the 10 participants. However, elevated liver-function tests occurred in high-dose participants and required treatment under the study protocol. One participant experienced a serious Grade 3 ventricular tachycardia event three months after dosing and the participant recovered following anti-arrhythmic treatment.
Bottom of Form
About the Author
Ben Hansel is a financial and business writer with a background in business, sales, and finance. He graduated from the University of Texas at El Paso. His professional and educational background informs his coverage of financial markets, corporate developments, economic trends and the broader forces shaping the market.
Important Editorial Note: 247MarketNews highlights companies approaching significant catalysts and inflection points. This report reflects information available at the time of publication. Since developments can occur rapidly, readers should independently verify current information and review all company filings and disclosures.